1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Drugs In Development, 2022, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Myocardial Fibrosis - Overview
- Myocardial Fibrosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myocardial Fibrosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myocardial Fibrosis - Companies Involved in Therapeutics Development
- Evotec SE
- Galectin Therapeutics Inc
- Guangdong Maijinjia Biotechnologies Co Ltd
- Invivosciences Inc
- Lead Discovery Center GmbH
- MandalMed Inc
- NovoMedix LLC
- Palatin Technologies Inc
- Pharmaxis Ltd
- Puretech Health Plc
- TRACON Pharmaceuticals Inc
- Vectus Biosystems Ltd
- Myocardial Fibrosis - Drug Profiles
- belapectin - Drug Profile
- Product Description
- Mechanism Of Action
- deupirfenidone - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs for Tissue Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- Fibrosis in Heart Muscle - Drug Profile
- Product Description
- Mechanism Of Action
- GMCT-01 - Drug Profile
- Product Description
- Mechanism Of Action
- GYY-4137 - Drug Profile
- Product Description
- Mechanism Of Action
- IVS-201 - Drug Profile
- Product Description
- Mechanism Of Action
- IVS-202 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- NM-922 - Drug Profile
- Product Description
- Mechanism Of Action
- PL-5028 - Drug Profile
- Product Description
- Mechanism Of Action
- PN1-Ab - Drug Profile
- Product Description
- Mechanism Of Action
- PXS-5153A - Drug Profile
- Product Description
- Mechanism Of Action
- PXS-5382A - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- RHO GEF - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- TPI-2049 - Drug Profile
- Product Description
- Mechanism Of Action
- TRC-205 - Drug Profile
- Product Description
- Mechanism Of Action
- VB-0004 - Drug Profile
- Product Description
- Mechanism Of Action
- Myocardial Fibrosis - Dormant Projects
- Myocardial Fibrosis - Discontinued Products
- Myocardial Fibrosis - Product Development Milestones
- Featured News & Press Releases
- Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP
- Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Myocardial Fibrosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Myocardial Fibrosis - Pipeline by Evotec SE, 2022
- Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, 2022
- Myocardial Fibrosis - Pipeline by Guangdong Maijinjia Biotechnologies Co Ltd, 2022
- Myocardial Fibrosis - Pipeline by Invivosciences Inc, 2022
- Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, 2022
- Myocardial Fibrosis - Pipeline by MandalMed Inc, 2022
- Myocardial Fibrosis - Pipeline by NovoMedix LLC, 2022
- Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, 2022
- Myocardial Fibrosis - Pipeline by Pharmaxis Ltd, 2022
- Myocardial Fibrosis - Pipeline by Puretech Health Plc, 2022
- Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, 2022
- Myocardial Fibrosis - Pipeline by Vectus Biosystems Ltd, 2022
- Myocardial Fibrosis - Dormant Projects, 2022
- Myocardial Fibrosis - Discontinued Products, 2022
- Number of Products under Development for Myocardial Fibrosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Evotec SE
- Galectin Therapeutics Inc
- Guangdong Maijinjia Biotechnologies Co Ltd
- Invivosciences Inc
- Lead Discovery Center GmbH
- MandalMed Inc
- NovoMedix LLC
- Palatin Technologies Inc
- Pharmaxis Ltd
- Puretech Health Plc
- TRACON Pharmaceuticals Inc
- Vectus Biosystems Ltd
